Breaking News, Collaborations & Alliances

Selexis, Inotrem Partner to Advance Inotrem’s Inflammatory Disease Program

Inotrem will leverage Selexis’ SUREtechnology Platform, a suite of cell line development technologies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

p.p1 {margin: 0.0px 0.0px 8.0px 0.0px; font: 11.0px ‘Trebuchet MS’} p.p2 {margin: 0.0px 0.0px 8.0px 0.0px; font: 11.0px ‘Trebuchet MS’; min-height: 12.0px} span.s1 {letter-spacing: 0.0px} Selexis SA, a JSR Life Sciences company, and Inotrem SA, a clinical-stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, have signed a service agreement to develop the cell line for Inotrem’s antibody-based candidate to address chronic ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters